TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.
Hansoh Pharmaceutical Group has entered into a license agreement with F. Hoffmann-La Roche Ltd, granting Roche an exclusive worldwide license to develop, manufacture, and commercialize Hansoh’s investigational CDH17-targeting antibody-drug conjugate, HS-20110, for colorectal cancer and other solid tumors. This agreement, which excludes the Chinese Mainland, Hong Kong, Macau, and Taiwan, involves an upfront payment of $80 million and potential milestone payments up to $1.45 billion, along with tiered royalties on future sales. This strategic partnership is expected to enhance Hansoh’s scientific and commercial capabilities, positioning it favorably in the global pharmaceutical market.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, incorporated in the Cayman Islands, operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is particularly engaged in creating treatments for cancer and other serious diseases, leveraging its advanced technology platforms to enhance its market presence.
Average Trading Volume: 12,260,863
Technical Sentiment Signal: Buy
Current Market Cap: HK$212.7B
See more insights into 3692 stock on TipRanks’ Stock Analysis page.